In 98 adolescents aged 12–17 with moderate to severe chronic hand eczema, delgocitinib cream gave IGA-CHE treatment success at week 16 in 64% vs 29% with vehicle cream. Adverse events: 50% vs 33%, all mild or moderate; no serious events.
RCTn = 98
Molin et al. Delgocitinib cream for adolescents with moderate to severe chronic hand eczema (DELTA TEEN): a multicentre, double-blind, phase 3 randomised controlled trial